These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 36796322)

  • 1. Conversion of locally advanced to resectable pancreatic body cancer aided by phosphorus-32 brachytherapy (OncoSil).
    Welsh F; Goodwin B; Lanka L; Allen B; Wong J; Weilert F
    N Z Med J; 2023 Feb; 136(1570):78-80. PubMed ID: 36796322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preoperative chemotherapy, radiotherapy, and surgical resection of locally advanced pancreatic cancer.
    Wanebo HJ; Glicksman AS; Vezeridis MP; Clark J; Tibbetts L; Koness RJ; Levy A
    Arch Surg; 2000 Jan; 135(1):81-7; discussion 88. PubMed ID: 10636353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcomes in borderline and locally advanced pancreatic cancer with the addition of low-dose-rate brachytherapy to standard of care therapy.
    Taylor RJ; Matthews GJ; Aseltine RH; Fields EC
    Brachytherapy; 2024; 23(3):355-359. PubMed ID: 38402046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contemporary trials evaluating neoadjuvant therapy for resectable pancreatic cancer.
    Chawla A
    J Surg Oncol; 2021 May; 123(6):1423-1431. PubMed ID: 33831254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathologic response with neoadjuvant chemotherapy and stereotactic body radiotherapy for borderline resectable and locally-advanced pancreatic cancer.
    Rajagopalan MS; Heron DE; Wegner RE; Zeh HJ; Bahary N; Krasinskas AM; Lembersky B; Brand R; Moser AJ; Quinn AE; Burton SA
    Radiat Oncol; 2013 Oct; 8():254. PubMed ID: 24175982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Postoperative complications after resection of borderline resectable and locally advanced pancreatic cancer: The impact of neoadjuvant chemotherapy with conventional radiation or stereotactic body radiation therapy.
    Blair AB; Rosati LM; Rezaee N; Gemenetzis G; Zheng L; Hruban RH; Cameron JL; Weiss MJ; Wolfgang CL; Herman JM; He J
    Surgery; 2018 May; 163(5):1090-1096. PubMed ID: 29395234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First report on the feasibility of a permanently implantable uni-directional planar low dose rate brachytherapy sheet for patients with resectable or borderline resectable pancreatic cancer.
    Dault JB; Todor D; Kaplan BJ; Myers JL; Fields EC
    Brachytherapy; 2021; 20(1):207-217. PubMed ID: 32978081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Randomized, Phase II, Clinical Trial of Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable, Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma.
    Saif A; Verbus E; Erickson B; Kamgar M; Tsai S; Evans D; Hernandez JM; Hall WA
    Ann Surg Oncol; 2023 Feb; 30(2):688-690. PubMed ID: 36427115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary resection versus neoadjuvant chemoradiation followed by resection for locally resectable or potentially resectable pancreatic carcinoma without distant metastasis. A multi-centre prospectively randomised phase II-study of the Interdisciplinary Working Group Gastrointestinal Tumours (AIO, ARO, and CAO).
    Brunner TB; Grabenbauer GG; Meyer T; Golcher H; Sauer R; Hohenberger W
    BMC Cancer; 2007 Mar; 7():41. PubMed ID: 17338829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette study.
    Heinrich S; Besselink M; Moehler M; van Laethem JL; Ducreux M; Grimminger P; Mittler J; Lang H; Lutz MP; Lesurtel M;
    BMC Cancer; 2019 Jul; 19(1):675. PubMed ID: 31288786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CivaSheet intraoperative radiation therapy for pancreatic cancer.
    Taylor RJ; Todor D; Kaplan BJ; Stover W; Fields EC
    Brachytherapy; 2022; 21(2):255-259. PubMed ID: 35031255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of radiation therapy in the management of pancreatic cancer.
    Goodman KA; Hajj C
    J Surg Oncol; 2013 Jan; 107(1):86-96. PubMed ID: 22532174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resection rates and intention-to-treat outcomes in borderline and locally advanced pancreatic cancer: real-world data from a population-based, prospective cohort study (NORPACT-2).
    Farnes I; Kleive D; Verbeke CS; Aabakken L; Issa-Epe A; Småstuen MC; Fosby BV; Dueland S; Line PD; Labori KJ
    BJS Open; 2023 Nov; 7(6):. PubMed ID: 38155512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant vs adjuvant therapy for resectable pancreatic cancer: the evolving role of radiation.
    Hoffe S; Rao N; Shridhar R
    Semin Radiat Oncol; 2014 Apr; 24(2):113-25. PubMed ID: 24635868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A neoadjuvant strategy for the management of nonmetastatic pancreatic cancer.
    Goff SL; Chabot JA
    Cancer J; 2012; 18(6):602-8. PubMed ID: 23187848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peptide receptor radionuclide therapy as neoadjuvant therapy for resectable or potentially resectable pancreatic neuroendocrine neoplasms.
    Partelli S; Bertani E; Bartolomei M; Perali C; Muffatti F; Grana CM; Schiavo Lena M; Doglioni C; Crippa S; Fazio N; Zamboni G; Falconi M
    Surgery; 2018 Apr; 163(4):761-767. PubMed ID: 29284590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surgical resection rates after neoadjuvant therapy for localized pancreatic ductal adenocarcinoma: meta-analysis.
    Brown ZJ; Heh V; Labiner HE; Brock GN; Ejaz A; Dillhoff M; Tsung A; Pawlik TM; Cloyd JM
    Br J Surg; 2022 Dec; 110(1):34-42. PubMed ID: 36346716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparing upfront surgery with neoadjuvant treatments in patients with resectable, borderline resectable or locally advanced pancreatic cancer: a systematic review and network meta-analysis of randomized clinical trials.
    He J; Lv N; Yang Z; Luo Y; Zhong W; Wu C
    Int J Surg; 2024 Jun; 110(6):3900-3909. PubMed ID: 38935819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival impact of distal pancreatectomy with en bloc celiac axis resection combined with neoadjuvant chemotherapy for borderline resectable or locally advanced pancreatic body carcinoma.
    Murakami Y; Nakagawa N; Kondo N; Hashimoto Y; Okada K; Seo S; Otsuka H
    Pancreatology; 2021 Apr; 21(3):564-572. PubMed ID: 33526385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brachytherapy and pancreatic cancer.
    Bodner WR; Hilaris BS
    Semin Surg Oncol; 1997; 13(3):204-7. PubMed ID: 9143059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.